A Trial on the Clinical and Socioeconomic Impact of Wearable Exoskeletons for Spinal Cord Injury Rehabilitation in the Spanish Healthcare System

ABLE Human Motion

Status: Enrolling

Conditions: Spinal Cord Injury

Treatments: Other: Conventional therapy; Device: ABLE Exoskeleton

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT07036107

Robotic-SNS

Details and patient eligibility

About

This clinical trial aims to collect evidence on the clinical benefits and the socioeconomic impact of integrating a novel wearable powered lower-limb exoskeleton for gait rehabilitation in acute/subacute spinal cord injured individuals and to evaluate the efficiency of this technology to the current standard of care in the Spanish Healthcare System (SNS).. The main questions it aims to answer are:

• Is robotic therapy for gait rehabilitation more effective and efficient than conventional therapy?
• Does robotic therapy for gait rehabilitation reduce the burden on healthcare professionals and caregivers?
• Does robotic therapy for gait rehabilitation reduce direct healthcare costs?
• Does robotic therapy for gait rehabilitation reduce intervention-related costs?

Researchers will compare a novel wearable powered lower-limb exoskeleton for gait rehabilitation to conventional therapy to see if the robotic exoskeleton is more effective and efficient in improving clinical benefits and to assess if it reduces the burden of healthcare professionals and caregivers, as well as healthcare and intervention-related costs.

Participants will:

• Be randomized on a 1:1 basis to receive rehabilitation treatment with either the robotic exoskeleton or conventional therapy for gait recovery, 3 times a week on non-consecutive days for 8 weeks (24-session program).
• Undergo a pre- and post-intervention assessment of clinical, functional, physiological, psychological, and socioeconomic variables.
• Have a follow-up visit 2 months after the end of the treatment.

Full description

Participants will be recruited from among patients admitted to the institutions involved in the project: Vall d'Hebron University Hospital (HVH) through its research institute (VHIR) and the National Hospital for Paraplegics of Toledo (HNP), through its research foundation (FHNP). After checking the inclusion and exclusion criteria, informing the patient and signing the consent, they will be randomly distributed between the control group (CG) and the intervention group (IG). Open random parallel groups. The IG will receive rehabilitation treatment with the ABLE Exoskeleton, while the CG will receive conventional therapy for gait rehabilitation. The latter includes joint mobilizations, strengthening of paretic muscles and re-education of walking with parallel bars, making use of the technical aids and orthoses required by the patient (KAFOs, crutches and walkers). For both groups, participation in the study is based on a baseline visit, the 24-session rehabilitation treatment (including mid-training and end-training assessments at 12-session and 24-session, respectively) and a follow-up visit two months after the end of the treatment. Caregiver overload will also be assessed at baseline visit, after patient's treatment and at the follow-up visit two months after patient treatment.

Enrollment: 80 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of spinal cord injury (SCI) in the acute or subacute phase (< 6 months of evolution)
• traumatic or non-traumatic aetiology
• neurological level of the SCI between C5 and L5 for patients with American Spinal Injury Association Impairment Scale (AIS) C or D, and SCI between C7 and L5 for patients with AIS A or B.
• sufficient strength in the upper extremities to handle a walker (triceps muscle score ≥ 4 according to the Medical Research Council (MRC) scale).
• range of motion (ROM) without limitations in the lower extremities (achieve at least a knee extension of 10 degrees and neutral ankle position)
• muscle spasticity in the lower extremities with a score ≤ 3 on the Modified Ashworth Scale (MAS)
• tolerate bipedalism (having stood up in the last year)
• aged between 18 and 70 years, with height between 150 cm and 190 cm, and weight less than 100 kg

Exclusion criteria

• WISCI ≥ 15
• cognitive or neurological limitations that prevent following instructions
• another neurologic disorder permanently affecting gait and gait therapy (other than SCI)
• grade I or higher in the European Pressure Ulcer Advisory Panel (EPUAP) in the areas of contact with the exoskeleton
• unresolved fractures at the time of the study
• uncontrolled autonomic dysautonomia
• intolerance to exercise
• uncontrolled epilepsy
• previous experience with Robotic-Assisted Gait Training (RAGT).
• ROM restriction such as flexing or arthrodesis will be excluded
• spinal instability (or spinal orthotics unless cleared by a medical doctor).
• deterioration >3 points of the total in the motor score of the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) in the last 4 weeks. Loss of sensation and/or motor activity above the level of injury detected that has not been evaluated by a doctor.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

80 participants in 2 patient groups

Robotic exoskeleton

Experimental group

Description:

The intervention group will receive rehabilitation treatment with the ABLE Exoskeleton

Treatment:

Device: ABLE Exoskeleton

Conventional therapy

Active Comparator group

Description:

The control group will receive conventional therapy for gait rehabilitation

Treatment:

Other: Conventional therapy